GC101 TIL Therapy Achieves Complete Tumor Response in Just 12 Weeks: World’s First Lymphodepletion-Free Autologous TIL Treatment Emerges as a Game-Changer for Lung Cancer
Juncell Therapeutics
Solid Tumor Cell Therapy Developer
Complete resolution of tumor target lesions in just 12 weeks! The world's first autologous TIL therapy without lymphodepletion becomes a "lifesaver" for lung cancer.
In April 2022, Mr. Zhang discovered a gradually worsening pain in his left chest and went to the hospital for detailed examinations, where he was diagnosed withLung AdenocarcinomaStage ⅣB, worse still, genetic testing revealed the presence ofKRAS G12D mutation, a genetic abnormality with extremely high malignancy, currently has no targeted drugs approved for marketing worldwide.
In order to control the condition as soon as possible, Mr. Zhang receivedThe combination of immunotherapy and chemotherapy, as well as the combination of immunotherapy, anti-angiogenic inhibitors, and chemotherapy, unfortunately, ultimatelyAll patients discontinued the medication due to disease progression or intolerance, and currently, there are no better treatment options available in clinical practice.His condition is still progressing rapidly.
Fortunately, a well-known cancer center in China is conducting a new type of cellular immunotherapy --GC101 TILThe clinical trial, in September 2024, Mr. Zhang successfully enrolled in this study.
GC101 TIL Cell Therapy, developed by Juncell Therapeutics using the DeepTIL® cell expansion platform, can cultivate a sufficient number of highly active TIL cells without high concentrations of IL-2 and feeder cells, and it is not dependent on IL-2.In clinical applications, GC101 eliminates the need for lymphodepletion and any dose of IL-2 injection, effectively addressing the clinical pain points associated with conventional TIL therapies that rely on high-dose chemotherapy for lymphodepletion and high-dose IL-2 injections.
Doctors isolated immune cells known as tumor-infiltrating lymphocytes (TILs) from the tumor surgically removed from Mr. Zhang. These immune cells are like a "dare-to-die squad" that infiltrates enemy lines to engage in close combat with cancer cells, possessing the strongest recognition and killing capabilities. By culturing and expanding these rare but extremely valuable immune cells in the laboratory, billions of TILs with enhanced combat power and massively increased numbers can be obtained. Once infused back into the patient’s body, these cells will continuously seek out and destroy cancer cells.As time goes by, this"Living" Cell TherapySustainably effective, when cancer cells reappear in the body, these immune cells can quickly launch an attack.
Surprising changes began to appear after receiving GC101 TIL therapy. During the treatment process, apart from transient hematological toxicity during the preconditioning phase, no other adverse reactions occurred.
At the 6th week after treatment, a miracle began to appear: the tumor shrank by 45%, tumor markers returned to normal, cancer pain was alleviated, and cervical lymph nodes disappeared.
By the 12th week, the large tumor target lesions had completely disappeared, achieving a complete response (CR). At 18 weeks, the CR status was still ongoing. This means that with just a single dose, GC101 TIL can continuously exert its tumor-killing effects, leaving cancer cells nowhere to hide.
As the tumor disappeared, Mr. Zhang's life underwent an earth-shaking change. His health condition continued to improve, thanks to the long-lasting effects of TIL therapy, he no longer needs frequent hospital visits for additional treatments and can attend regular follow-ups without family assistance. In daily life, he is fully self-reliant, returning to a normal family life and enjoying every moment spent with his family.
(Note: To protect patient privacy, pseudonyms are used in the text, and details about the conditions and treatments have been slightly edited. For access to the original literature, click the link at the end of the article.)
Believe that after watching the above inspiring cases, patients must be curious about the therapy Mr. Zhang received.
GC101 isJuncell Therapeutics (Shanghai)Successfully DevelopedThe World's First Natural TIL Cell Therapy Without Lymphodepletion and IL-2 Injection, and was approved by the National Medical Products Administration (NMPA) in April 2022 to enter Phase I clinical trials.Currently, it has entered the pivotal Phase II clinical trial (MIZAR-003) and is recruiting patients across 24 centers in 20 provinces (municipalities and autonomous regions) of China.
Clinical data show:For advanced malignant solid tumors such as lung cancer, melanoma, and cervical cancer,GC101 Achieves an Objective Response Rate (ORR) of Over 38%, with Four Patients Experiencing Complete Tumor Clearance, Reaching Complete Response (CR). The Longest Disease-Free Survival Time Has Exceeded Two Years. Additionally, Six Patients Have Achieved Partial Response (PR) with Tumor Reduction Greater Than 30%.
This domestically innovative TIL therapy, developed in China, differs from the U.S.-approved AMTAGVI™ (Lifileucel). All patients only need to stay in a general ward to receive treatment before the TIL cell infusion.No need to undergo high-intensity non-myeloablative lymphodepletion preconditioning, and no infusion of any dose of IL-2 is required after TIL cell infusion.The simplified clinical protocol can still ensure the effective proliferation of TIL cells in patients.Maximally Avoid AMTAGVI™ Black Box Warning-Related Adverse Reactions(such as: treatment-related mortality events, persistent severe cytopenia, serious infections, cardiopulmonary and renal function impairment, etc.) occurrence risk,Greatly improve the safety, convenience, and accessibility of TIL therapy.
The good news is that, currentlyClinical trials of GC101 for advanced melanoma and solid tumors are still ongoing, and many patients have successfully enrolled through the Global Cancer Doctors Network.
Aged 18-75, male or female, without severe underlying diseases;
Suffering from only one type of malignant solid tumor,Malignant Melanoma,Lung cancer, squamous cell carcinoma of the head and neck, esophageal squamous cell carcinoma, cervical cancer, endometrial cancer, etc. are prioritized;
Failed after standard treatment or lack of effective treatment methods;
At least two lesions are present, the patient's physical condition supports surgical sampling, and the sampled lesions have not undergone local treatments (such as radiotherapy, radiofrequency therapy, oncolytic virus, oncolytic bacteria, etc.).
If you are looking for help with TILs and other new domestic and international anti-cancer treatments, and your financial situation allows, you can first submit your medical records to the Medical Department of Global Oncology Doctors Network (400-666-7998) for an initial evaluation. Once approved, there is a chance to receive free treatment with "astronomically priced" therapies.
TIL TherapyThe approval reflects a significant advancement in the field of immunotherapy, which uses autologous immune cells to combat cancer.An increasing number of doctors will be able to provide personalized "tailor-made" treatment plans for the right patients at the right time!And with the attention from the country and relevant departments, numerous China-based enterprises have made breakthroughs in solvingTILKey Common Issues in Therapy,AchieveTILCell“Raise well, raise effectively, afford easily, use smoothly”The multi-level target,Covering multiple types of solid tumors.We believe that these effective anti-cancer therapies will accelerate their launch and inclusion in medical insurance in China, benefiting more people. We look forward to it together!With the development of more treatment options, patients with advanced tumors will have more treatment choices and hope, IWe look forward to the day when humanity conquers cancer arriving soon.
Source of the case:Juncell Therapeutics
This article is original content from Global Oncology Doctors Network. Unauthorized reproduction is strictly prohibited.
Scan to Add Patient Group
Cancer News｜New Technologies｜New Drug Development｜Leading Experts
Join the group to receive free anti-cancer resources
